NIK‑ and IKKβ‑binding protein contributes to gastric cancer chemoresistance by promoting epithelial‑mesenchymal transition through the NF‑κB signaling pathway

Fu,Zhen‑Hua; Liu,Shi‑Quan; Qin,Meng‑Bin; Huang,Jie‑An; Xu,Chun‑Yan; Wu,Wen‑Hong; Zhu,Li‑Ye; Qin,Nan; Lai,Ming‑Yu

doi:10.3892/or.2018.6348

NIK‑ and IKKβ‑binding protein contributes to gastric cancer chemoresistance by promoting epithelial‑mesenchymal transition through the NF‑κB signaling pathway

Authors:
- Zhen‑Hua Fu
- Shi‑Quan Liu
- Meng‑Bin Qin
- Jie‑An Huang
- Chun‑Yan Xu
- Wen‑Hong Wu
- Li‑Ye Zhu
- Nan Qin
- Ming‑Yu Lai
View Affiliations

Affiliations: Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: March 30, 2018 https://doi.org/10.3892/or.2018.6348
Pages: 2721-2730

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systematic chemotherapy is indispensable for gastric cancer patients with advanced stage disease, but the occurrence of chemoresistance drastically limits treatment effectiveness. There is a tremendous need for identifying the underlying mechanism of chemoresistance. NIK‑ and IKKβ‑binding protein (NIBP) (also known as TRAPPC9, trafficking protein particle complex 9) is a regulator of the cytokine‑induced NF‑κB signaling pathway which has been proven to play pivotal roles in the progression of various malignancies. Nevertheless, it is still ambiguous whether NIBP is involved in the chemoresistance of gastric cancer. The aim of the present study was to investigate the effect of NIBP on chemotherapy resistance of gastric cancer (GC) and to research the mechanisms of Ginkgo biloba extract 761 (EGb 761®) on reversing chemoresistence which has been confirmed in our previous study. In the present study, the results of immumohistochemisty revealed that the positive staining rates of NIBP, NF‑κB p65 and NF‑κB p‑p65 in gastric cancer tissues were obviously higher than those in normal tissues. Furthermore, a close correlation was found to exist between the expression of NIBP and NF‑κB p65 (p‑p65) in gastric cancer tissues. Moreover, the overexpression of NIBP was closely related to tumor differentiation, depth of invasion, clinical stage and lymphatic metastasis in gastric cancer. Western blot analysis, real‑time PCR, MTT assay and flow cytometric analysis were performed and the results demonstrated that compared with the gastric cancer SGC‑7901 cells, the expression of NIBP, NF‑κB p65, NF‑κB p‑p65 and mesenchymal marker vimentin were significantly increased in gastric cancer multidrug‑resistant SGC‑7901/CDDP cells, and the epithelial cell marker ZO‑1 was significantly decreased. Meanwhile, it was found that SGC‑7901/CDDP cells were accompanied by spindle‑like mesenchymal appearance and upregulation of stem cell marker CD133 which has been verified to be an upstream regulatory gene of epithelial‑mesenchymal transition (EMT). Further research confirmed that downregulation of NIBP by Ginkgo biloba extract (EGb) 761 EGb 761 suppressed the cis‑diamminedichloroplatinum(II) (CDDP)‑induced NF‑κB signaling pathway, EMT and the expression of CD133 in SGC‑7901 and SGC‑7901/CDDP cells. Altogether, these data indicate that the NIBP‑regulated NF‑κB signaling pathway plays a pivotal role in the chemoresistance of gastric cancer by promoting CD133‑induced EMT.

View Figures

View References

1	Zhang D and Fan D: Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther. 7:1369–1378. 2007. View Article : Google Scholar : PubMed/NCBI
2	Hu WH, Pendergast JS, Mo XM, Brambilla R, Bracchi-Ricard V, Li F, Walters WM, Blits B, He L, Schaal SM, et al: NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF(kappa)B activation. J Biol Chem. 280:29233–29241. 2005. View Article : Google Scholar : PubMed/NCBI
3	Zong M, Satoh A, Yu MK, Siu KY, Ng WY, Chan HC, Tanner JA and Yu S: TRAPPC9 mediates the interaction between p150^Glued and COPII vesicles at the target membrane. PLoS One. 7:e299952012. View Article : Google Scholar : PubMed/NCBI
4	Zhang Y, Bitner D, Filho Pontes AA, Li F, Liu S, Wang H, Yang F, Adhikari S, Gordon J, Srinivasan S and Hu W: Expression and function of NIK- and IKK2-binding protein (NIBP) in mouse enteric nervous system. Neurogastroenterol Motil. 26:77–97. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013. View Article : Google Scholar : PubMed/NCBI
6	Vaiopoulos AG, Athanasoula KC and Papavassiliou AG: NF-kappaB in colorectal cancer. J Mol Med. 91:1029–1037. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xu C, Qin M, Tan L, Liu S and Huang J: NIBP impacts on the expression of E-cadherin, CD44 and vimentin in colon cancer via the NF-κB pathway. Mol Med Rep. 13:5379–5385. 2016. View Article : Google Scholar : PubMed/NCBI
8	Tan L, Liu SQ, Qin MB, et al: Relationship between expression of NIBP and noncanonical NF-κB signaling: Clinical significance in colon carcinoma. World Chin J Diges. 23:1238–1246. 2015. View Article : Google Scholar
9	Zhang Y, Liu S, Wang H, Yang W, Li F, Yang F, Yu D, Ramsey FV, Tuszyski GP and Hu W: Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NF-κB signaling. Oncotarget. 6:6160–6178. 2015.PubMed/NCBI
10	Thiery JP, Acloque H, Huang RYJ and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
11	Shang Y, Cai X and Fan D: Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets. 13:915–929. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R: Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
13	Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J and Xu Y: NF-kappaB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int J Oncol. 48:225–234. 2016. View Article : Google Scholar : PubMed/NCBI
14	Mao YB, Liu SQ, Tan L, Zhou Q and Huang JA: EGb761 enhances cisplatin and etoposide-induced apoptosis of human gastric cancer SGC-7901 cells. World Chin J Diges. 21:3330–3337. 2013. View Article : Google Scholar
15	Soltanian S and Matin MM: Cancer stem cells and cancer therapy. Tumour Biol. 32:425–440. 2011. View Article : Google Scholar : PubMed/NCBI
16	Weng CC, Kuo KK, Su HT, Hsiao PJ, Chen YW, Wu DC, Hung WC and Cheng KH: Pancreatic tumor progression associated with CD133 overexpression: Involvement of increased TERT expression and epidermal growth factor receptor-dependent Akt activation. Pancreas. 45:443–457. 2016. View Article : Google Scholar : PubMed/NCBI
17	Nomura A, Banerjee S, Chugh R, Dudeja V, Yamamoto M, Vickers SM and Saluja AK: CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget. 6:8313–8322. 2015. View Article : Google Scholar : PubMed/NCBI
18	Liu YM, Li XF, Liu H and Wu XL: Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. Oncol Rep. 34:2977–2986. 2015. View Article : Google Scholar : PubMed/NCBI
19	Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S and Miyagi Y: NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells. Biochem Biophys Res Commun. 423:667–671. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zou W, Ma X, Hua W, Chen B and Cai G: Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway. Oncol Rep. 34:3256–3263. 2015. View Article : Google Scholar : PubMed/NCBI
21	Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, Qu L, Shou C and Zhao Z: Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep. 6:205022016. View Article : Google Scholar : PubMed/NCBI
22	Zhang K, Jiao X, Liu X, Zhang B, Wang J, Wang Q, Tao Y and Zhang D: Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation. Int J Mol Sci. 11:4891–4902. 2010. View Article : Google Scholar : PubMed/NCBI
23	Wu W, Yang JL, Wang YL, Wang H, Yao M, Wang L, Gu JJ, Cai Y, Shi Y and Yao DF: Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription. World J Hepatol. 8:985–993. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X, Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death Dis. 4:e8472013. View Article : Google Scholar : PubMed/NCBI
25	Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP and Mori S: Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 34:1899–1907. 2015. View Article : Google Scholar : PubMed/NCBI
26	Jia ZF, Wu YH, Cao DH, Cao XY, Jiang J and Zhou BS: Polymorphisms of cancer stem cell marker gene CD133 are associated with susceptibility and prognosis of gastric cancer. Future Oncol. 13:979–989. 2017. View Article : Google Scholar : PubMed/NCBI
27	Moon YH, Kim D, Sohn HM and Lim W: Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines. Clin Exp Metastasis. 33:487–496. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ding Q, Yoshimitsu M, Kuwahata T, Maeda K, Hayashi T, Obara T, Miyazaki Y, Matsubara S, Natsugoe S and Takao S: Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Hum Cell. 25:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
29	Tu Z, Xie S, Xiong M, Liu Y, Yang X, Tembo KM, Huang J, Hu W, Huang X, Pan S, et al: CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer. Int J Oncol. 50:505–514. 2017. View Article : Google Scholar : PubMed/NCBI